A study of hypnotic drugs in patients with chronic diseases: Comparative efficacy of placebo; methyprylon (cas 125-64-4) (Noludar); meprobamate (Miltown, Equanil) pentobarbital; phenobarbital; secobarbital☆☆☆★

Add time:09/26/2019    Source:sciencedirect.com

1.1. A controlled clinical comparison has been made of placebo, pentobarbital, secobarbital, phenobarbital, methyprylon (cas 125-64-4) (Noludar), and meprobamate (Miltown Equanil), in 46 chronically ill patients.2.2. The effects of two dose levels of each drug on induction and duration of sleep, and over-all performance, as described by the patients, have been described and analyzed.3.3. Methyprylon (Noludar) and meprobamate (Miltown Equanil) have hypnotic properties, the former resembling pentobarbital and secobarbital, and the latter resembling phenobarbital, in performance.4.4. The most satisfactory therapeutic results were achieved with 0.2 Gm. of secobarbital and of pentobarbital; these drugs are recommended as standards against which new drugs should be compared.5.5. Unpleasant side effects were infrequent with all medications.6.6. Chronically ill patients with insomnia provide a useful population for the evaluation of hypnotic drugs.

We also recommend Trading Suppliers and Manufacturers of methyprylon (cas 125-64-4). Pls Click Website Link as below: cas 125-64-4 suppliers

Prev:The determination of methyprylon (cas 125-64-4) and its metabolites in biological fluids by gas chromatography
Next:Enhanced metabolism of methyprylon (cas 125-64-4), meprobamate, and chlordiazepoxide hydrochloride after chronic feeding of a low dietary level of DDT to male and female rats)